Med BioGene Receives Funding from National Research Council Canada to Develop Genetic Biomarkers for Cardiovascular Disease
"We believe that Med BioGene's expertise in gene expression and the continued development and validation of our genetic signatures for CVD, coupled with access to world-class scientific knowledge and blood samples from patients with confirmed CVD through our collaboration with the University of Ottawa Heart Institute, will create an effective environment for the development of a novel tool for use in screening and in improving diagnosis, prognosis and treatment decisions for patients suffering from CVD" said Erinn Broshko, Chief Executive Officer of MBI.
Organizations
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.